Ibrutinib + Bendamustine/Rituximab in Patients with Previously Treated CLL/SLL
2,112 views · Published 16 November 2015 · 8:51 · Indexed 6 November 2026
Channel: American Society of Hematology · 2015 · Nonprofits & Activism
The combination of ibrutinib and bendamustine/rituximab (BR) was well-tolerated and did not significantly affect the safety profile of BR in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma, according to an analysis of the HELIOS trial presented at the 2015 ASH Meeting on Hematologic Malignancies. Dr. Chanan-Khan discusses the results.
More from this channel
-
1:52
Ron Reagan Accepts ASH Award - Stem Cell Research
-
4:25
Sen. Jim Talent's Work on Sickle Cell Disease Legislation
-
3:56
ASH and the Reagans Support Stem Cell Research
-
5:42
The American Society of Hematology Celebrates its 50th Anniversary
-
5:57
David Nathan Receives 2011 Wallace H. Coulter Award for Lifetime Achievement in Hematology
-
5:17
James George Receives 2012 Wallace H. Coulter Award for Lifetime Achievement in Hematology
-
2:21
Congress: Protect NIH funding
-
2:21
Act Now: Tell Congress to Stop Further Cuts to Research Funding